Verastem Inc., a biopharmaceutical company specializing in treatments for RAS/MAPK pathway-driven cancers, has announced the FDA's accelerated approval of its drug combination, avutometinib plus defactinib, for patients with KRAS-mutated recurrent low-grade serous ovarian cancer. This approval is based on the promising results from the Phase 2 RAMP 201 trial, which demonstrated a 31% overall response rate. The approval marks a significant advancement in the treatment of this rare form of ovarian cancer, highlighting the potential for this drug combination to become the new standard of care. The combination is also being evaluated in the ongoing global Phase 3 RAMP 301 trial for broader applications in recurrent low-grade serous ovarian cancer, regardless of KRAS mutation status.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.